---
title: "Survodutide"
canonical_url: https://peptidelibrary.app/library/survodutide
description: "Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Survodutide

Survodutide (also called BI 456906 or GLP-1/glucagon dual agonist) is a glucagon agonist in the GLP-1 Agonist class. Survodutide is a dual agonist at the glucagon and GLP-1 receptors, acylated for weekly dosing. GLP-1 receptor activation reduces energy intake through central appetite circuits and improves glucose-dependent insulin secretion, while glucagon receptor activation increases hepatic energy expenditure and stimulates fatty-acid oxidation in the liver.

Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication.

Also known as: BI 456906, GLP-1/glucagon dual agonist.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational GLP-1/glucagon agonist
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Survodutide is a dual agonist at the glucagon and GLP-1 receptors, acylated for weekly dosing. GLP-1 receptor activation reduces energy intake through central appetite circuits and improves glucose-dependent insulin secretion, while glucagon receptor activation increases hepatic energy expenditure and stimulates fatty-acid oxidation in the liver. The hepatic component is the reason the class is being investigated in metabolic dysfunction-associated steatohepatitis as well as obesity, since glucagon signalling directly reduces hepatic lipid content. The design constraint is that unopposed glucagon agonism raises glucose, so the ratio of glucagon to GLP-1 activity determines whether the net glycaemic effect is favourable.

Targets: GLP-1 receptor, Glucagon receptor.

Origin: Synthetic peptide dual agonist.

## Properties

- Molecular formula: C192H289N47O61
- Molecular weight: ≈4232 g/mol
- CAS number: 2805997-46-8
- Half-life: ~6 days (once-weekly)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. 2024. Controlled human trial. Population: Adults aged 18–75 with BMI ≥27 and without diabetes (n=386 treated) [Source](https://pubmed.ncbi.nlm.nih.gov/38330987/)
2. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. 2024. Controlled human trial. Population: Adults with metabolic dysfunction-associated steatohepatitis and fibrosis. Improvement in MASH without worsening of fibrosis [Source](https://pubmed.ncbi.nlm.nih.gov/38847460/)
3. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. 2026. Controlled human trial. Population: Adults with BMI ≥30, or ≥27 with an obesity-related condition. Body weight [Source](https://pubmed.ncbi.nlm.nih.gov/42253238/)
4. NCT06077864 — A Study to Test the Effect of Survodutide on Cardiovascular Outcomes. Human study (early or uncontrolled). Population: Adults with obesity (n=5531). Cardiovascular outcomes. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT06077864)

### Registered trials

- [NCT06077864](https://clinicaltrials.gov/study/NCT06077864)

## Safety

Side effects: GI AEs; Increased heart rate.

Risks: Not approved; WADA S0.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Survodutide has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Survodutide?

Investigational dual agonist at the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma and studied in phase 3 trials for obesity and for metabolic dysfunction-associated steatohepatitis. The glucagon component acts directly on hepatocytes to increase energy expenditure and fat oxidation, which is why liver endpoints feature alongside weight. Not FDA-approved for any indication.

### Is Survodutide FDA approved?

No. Survodutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### What is the half-life of Survodutide?

Reported half-life for Survodutide is ~6 days (once-weekly). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Survodutide banned in sport?

Survodutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Survodutide?

Compounds most often compared with Survodutide include Retatrutide, Pemvidutide, Cotadutide and Mazdutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Survodutide Once Weekly for the Treatment of Adults with Obesity — N Engl J Med, 2026](https://pubmed.ncbi.nlm.nih.gov/42253238/)
- [Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes — Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/41216778/)
- [Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity — Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/42331726/)
- [Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) — Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/41187967/)
- [Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial — Nat Med, 2026](https://pubmed.ncbi.nlm.nih.gov/42252333/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
